FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W125344597> ?p ?o ?g. }

• W125344597 endingPage "27S" @default.
• W125344597 startingPage "21S" @default.
• W125344597 abstract "Iodine-131 anti-B1 antibody radioimmunotherapy for B-cell lymphoma was previously reported to have substantial antitumor activity in B-cell non-Hodgkin's lymphoma (NHL) after failures of standard and salvage chemotherapy. In this article, the University of Michigan Phase I clinical experience is updated, with follow-up of up to 6 yr since initial treatment reported.Thirty-four patients with CD20-expressing NHL were first studied with one or more dosimetric doses of approximately 5 mCi of 1311 anti-B1 antibody (after varying predoses of unlabeled anti-B1 antibody). They were then treated with a patient-specific radioimmunotherapeutic dose designed to deliver a specified radiation dose to the whole body of between 25 and 85 cGy. Patients were observed for toxicity and tumor response.Seventeen (50%) patients had low-grade NHL, 9 (26%) had low-grade transformed NHL and 8 (24%) had de novo intermediate-grade NHL. At study entry, 17 (50%) had an elevated lactate dehydrogenase level, 12 (35%) had high tumor burden and 18 (53%) had not responded to their last chemotherapy. The median number of prior NHL therapies was 4.1. Twenty-eight of 34 patients completed treatment, with 22 of 28 (79%) achieving a response and 14 of 28 (50%) achieving a complete response (CR). The median duration of response was 357 days. The median duration of response for CRs was 471 days, with 4 CRs having a duration of > 1000 days (maximum = > 1460 days). Bone marrow toxicity was dose-limiting and dependent on the total-body dose (TBD) of radiation. Thrombocytopenia appeared to be more marked in patients with prior bone marrow transplantation. The TBD of 75 cGy was established as the maximum tolerated dose in patients who had not had prior bone marrow transplantation. Duration of CR was significantly longer (p < 0.04) in patients who received a TBD of 65-75 cGy (1109 days) than it was in those who received a lower TBD of 25-60 cGy (385 days). Four of 34 (12%) patients developed detectable human antimouse antibody levels. The median survival from study entry for all patients was 1508 days (range = 63 to >2226 days). Sixteen of 17 patients who achieved a response of > or = 6 mo duration remain alive.This update of the Phase I results after 1311 anti-B1 antibody treatment for NHL indicates that CRs can be durable and that survival can be of long duration. This form of therapy for NHL should have increasing application in clinical practice after confirmation of these results in larger multicenter studies." @default.
• W125344597 created "2016-06-24" @default.
• W125344597 creator A5010724563 @default.
• W125344597 creator A5021222020 @default.
• W125344597 creator A5022347541 @default.
• W125344597 creator A5024041886 @default.
• W125344597 creator A5024722162 @default.
• W125344597 creator A5052209029 @default.
• W125344597 creator A5059865994 @default.
• W125344597 creator A5080366682 @default.
• W125344597 creator A5080796049 @default.
• W125344597 creator A5086541480 @default.
• W125344597 date "1998-08-01" @default.
• W125344597 modified "2023-10-06" @default.
• W125344597 title "Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience." @default.
• W125344597 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9708567" @default.
• W125344597 hasPublicationYear "1998" @default.
• W125344597 type Work @default.
• W125344597 sameAs 125344597 @default.
• W125344597 citedByCount "37" @default.
• W125344597 countsByYear W1253445972012 @default.
• W125344597 countsByYear W1253445972013 @default.
• W125344597 countsByYear W1253445972015 @default.
• W125344597 countsByYear W1253445972019 @default.
• W125344597 countsByYear W1253445972020 @default.
• W125344597 crossrefType "journal-article" @default.
• W125344597 hasAuthorship W125344597A5010724563 @default.
• W125344597 hasAuthorship W125344597A5021222020 @default.
• W125344597 hasAuthorship W125344597A5022347541 @default.
• W125344597 hasAuthorship W125344597A5024041886 @default.
• W125344597 hasAuthorship W125344597A5024722162 @default.
• W125344597 hasAuthorship W125344597A5052209029 @default.
• W125344597 hasAuthorship W125344597A5059865994 @default.
• W125344597 hasAuthorship W125344597A5080366682 @default.
• W125344597 hasAuthorship W125344597A5080796049 @default.
• W125344597 hasAuthorship W125344597A5086541480 @default.
• W125344597 hasConcept C126322002 @default.
• W125344597 hasConcept C159654299 @default.
• W125344597 hasConcept C181199279 @default.
• W125344597 hasConcept C185592680 @default.
• W125344597 hasConcept C203014093 @default.
• W125344597 hasConcept C2776146153 @default.
• W125344597 hasConcept C2776694085 @default.
• W125344597 hasConcept C2777318727 @default.
• W125344597 hasConcept C2779338263 @default.
• W125344597 hasConcept C2780007613 @default.
• W125344597 hasConcept C29730261 @default.
• W125344597 hasConcept C2989005 @default.
• W125344597 hasConcept C542903549 @default.
• W125344597 hasConcept C55493867 @default.
• W125344597 hasConcept C71924100 @default.
• W125344597 hasConcept C90924648 @default.
• W125344597 hasConceptScore W125344597C126322002 @default.
• W125344597 hasConceptScore W125344597C159654299 @default.
• W125344597 hasConceptScore W125344597C181199279 @default.
• W125344597 hasConceptScore W125344597C185592680 @default.
• W125344597 hasConceptScore W125344597C203014093 @default.
• W125344597 hasConceptScore W125344597C2776146153 @default.
• W125344597 hasConceptScore W125344597C2776694085 @default.
• W125344597 hasConceptScore W125344597C2777318727 @default.
• W125344597 hasConceptScore W125344597C2779338263 @default.
• W125344597 hasConceptScore W125344597C2780007613 @default.
• W125344597 hasConceptScore W125344597C29730261 @default.
• W125344597 hasConceptScore W125344597C2989005 @default.
• W125344597 hasConceptScore W125344597C542903549 @default.
• W125344597 hasConceptScore W125344597C55493867 @default.
• W125344597 hasConceptScore W125344597C71924100 @default.
• W125344597 hasConceptScore W125344597C90924648 @default.
• W125344597 hasIssue "8 Suppl" @default.
• W125344597 hasLocation W1253445971 @default.
• W125344597 hasOpenAccess W125344597 @default.
• W125344597 hasPrimaryLocation W1253445971 @default.
• W125344597 hasRelatedWork W1517145497 @default.
• W125344597 hasRelatedWork W1970641137 @default.
• W125344597 hasRelatedWork W2012682427 @default.
• W125344597 hasRelatedWork W2062678527 @default.
• W125344597 hasRelatedWork W2072105586 @default.
• W125344597 hasRelatedWork W2093273184 @default.
• W125344597 hasRelatedWork W2139087516 @default.
• W125344597 hasRelatedWork W2160388570 @default.
• W125344597 hasRelatedWork W2380131577 @default.
• W125344597 hasRelatedWork W2182140886 @default.
• W125344597 hasVolume "39" @default.
• W125344597 isParatext "false" @default.
• W125344597 isRetracted "false" @default.
• W125344597 magId "125344597" @default.
• W125344597 workType "article" @default.